#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4360	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2672	485.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1863	1863	T	672	T	602	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4360	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2672	485.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1597	1597	C	661	C	564	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4360	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2672	485.7	0	HET	.	.	.	A922G	.	922	922	A	1335	1335	A	724	A,G	338,302	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6862	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3893	528.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1836	1836	A	589	A,C	522,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6862	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3893	528.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2470	2470	C	616	C,A	533,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6862	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3893	528.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2544	2544	A	637	A,C	548,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6862	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3893	528.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3096	3096	C	645	C,A,T	546,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	27	704	folP	852	852	99.88	folP.l15.c4.ctg.1	1897	111.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1580	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3714	127.5	1	SNP	p	S91F	0	.	.	271	273	TCC	772	774	TCC	148;146;146	T;C;C,A	131;131;130,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1580	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3714	127.5	1	SNP	p	D95N	0	.	.	283	285	GAC	784	786	GAC	145;146;146	G;A;C	127;130;129	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1580	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3714	127.5	1	SNP	p	D95G	0	.	.	283	285	GAC	784	786	GAC	145;146;146	G;A;C	127;130;129	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	612	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1704	107.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	649	651	ACC	171;171;171	A;C;C	143;145;145	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	612	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1704	107.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	847	849	CAC	168;167;167	C;A;C	145;144;146	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	612	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1704	107.9	0	.	p	.	0	E117K	NONSYN	349	351	GAA	883	885	AAA	173;173;172	A;A;A	151;150;149	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	612	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1704	107.9	1	SNP	p	G45D	0	.	.	133	135	GGC	667	669	GGC	171;171;172	G;G;C	146;143;145	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	412	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1203	102.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1809	1811	GCA	174;173;172	G;C;A	149;148;147	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2292	2294	ATT	130;130;130	A;T;T	121;122;123	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	1	SNP	p	D86N	0	.	.	256	258	GAC	762	764	GAC	171;171;172	G,A;A,T;C	143,1;141,1;147	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	1	SNP	p	S87R	0	.	.	259	261	AGT	765	767	AGT	171;172;172	A;G;T	147;152;143	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	1	SNP	p	S87I	0	.	.	259	261	AGT	765	767	AGT	171;172;172	A;G;T	147;152;143	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	1	SNP	p	S87W	0	.	.	259	261	AGT	765	767	AGT	171;172;172	A;G;T	147;152;143	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1414	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3287	129.0	1	SNP	p	S88P	0	.	.	262	264	TCC	768	770	TCC	173;173;172	T;C;C	153;146;149	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1304	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2984	131.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1712	1714	GGC	177;175;174	G;G;C	148;146;146	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1423	1425	GCA	166;164;163	G;C;A	142;147;147	penA.22.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1426	1428	ATC	164;164;165	A;T;C	147;146;147	penA.22.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1438	1440	GTG	165;167;169	G;T;G	148;148;147	penA.22.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1438	1440	GTG	165;167;169	G;T;G	148;148;147	penA.22.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1942	1944	ACC	177;178;177	A,C;C;C	146,1;148;149	penA.22.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1996	1998	GCG	169;169;168	G;C;G,T	141;130;134,1	penA.22.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1996	1998	GCG	169;169;168	G;C;G,T	141;130;134,1	penA.22.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2119	2121	GGT	161;161;161	G,C;G;T	143,1;149;143	penA.22.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2128	2130	GGC	159;159;157	G;G;C,T	144;143;139,1	penA.22.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1260	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2747	137.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2146	2148	CCG	164;165;166	C,T,G,A;C;G	143,2,1,1;148;146	penA.22.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1430	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3394	126.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	742	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2139	104.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	729	729	C	134	C	115	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	804	806	CAA	187;188;188	C,A;A;A	166,1;166;169	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	0	.	p	.	0	E212G	NONSYN	634	636	GAA	1011	1013	GGT	174;174;174	G,C;G;T,C	149,1;150;148,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1014	1016	GAT	175;177;177	G;A,G;T	149;149,1;148	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1020	1022	GCT	179;179;179	G;C;T	149;151;152	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1146	1148	AAG	169;168;169	A;A;G	147;146;145	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	854	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1560	152.6	1	SNP	p	G120K	0	.	.	358	360	GGC	735	737	GGC	185;186;188	G,T;G,C;C	163,1;161,1;165	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2924	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5141	170.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2112	2114	CAT	174;175;174	C;A;T	152;153;154	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	450	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1283	105.2	1	SNP	p	V57M	0	.	.	169	171	GTG	646	648	GTG	178;176;177	G;T;G	154;156;151	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
